Medicare utilization — DR. TERRI BAILEY PUSTILNIK (M.D.)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 45,390 | 43 | $0 | $17,959 |
| J1453 | Injection, fosaprepitant, 1 mg | 7,050 | 22 | $0 | $771 |
| J9271 | Injection, pembrolizumab, 1 mg | 5,200 | 12 | $0 | $224,560 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 5,145 | 20 | $0 | $11,985 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4,682 | 53 | $0 | $498 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·